NIH Pledges $3M for Pharmacogenomics Studies of Mood and Anxiety Disorders

NEW YORK, Sept. 5 (GenomeWeb News) - The National Institutes of Health announced today that it will commit $3 million in financial year 2004 to fund the use of genomic methods to track responses to drugs used to treat mood or anxiety disorders.

"The underlying theme of this RFA will be to search across the genome for pharmacogenetically important sequence variations by correlating genotype with treatment response," the Request for Applications stated. A particular focus, according to the NIH, will be the construction of haplotypes for pharmacogenetic prediction.